Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. Here, SLC10A2 is linked to metabolic dysfunction-associated steatohepatitis.